- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Study finds similar primary prevention benefits of lowering LDL cholesterol in younger and older statin users
Denmark: Findings from a recent study published in the Journal of the American College of Cardiology support a relative clinical benefit of LDL cholesterol lowering for primary prevention of major vascular events in people aged ≥70 years similar to in individuals aged <70 years.
The Danish nationwide cohort study found similar primary prevention benefits of lowering LDL cholesterol between statin users under and over the age of 70 years. The researchers revealed that each 1 mmol/L reduction in LDL cholesterol achieved was tied to a reduced risk of major vascular events in older (HR 0.77) and younger individuals alike (HR 0.76) following 2.5 years of follow-up, starting 1 year after the start of lipid-lowering therapy with statins alone or with other agents.
They reported that events prevented irrespective of the age cutoff were a composite of non-hemorrhagic stroke, acute coronary syndrome, and coronary revascularization -- all similarly reduced in a separate analysis using a cutoff of 75 years.
LDL (low-density lipoprotein) cholesterol with lipid-lowering therapy has consistently been shown to reduce the risk of cardiovascular disease (CVD) in primary prevention trials where the majority of individuals are aged <70 years. There is less clarity of evidence for older individuals.
In the study, Niklas Worm Andersson, Statens Serum Institut, Copenhagen, Denmark, and colleagues sought to compare the clinical effectiveness of lowering LDL cholesterol using lipid-lowering therapy for primary prevention of CVD among older and younger individuals in a Danish nationwide cohort.
They included individuals aged ≥50 years who had initiated lipid-lowering therapy from 2008 to 2017, had no history of atherosclerotic CVD, and had a baseline and a within-1-year LDL cholesterol measurement. They evaluated the associated risk of major vascular events among older individuals (≥70 years) by HRs per 1 mmol/L reduction in LDL cholesterol versus younger individuals (<70 years).
The study revealed the following findings:
- For both the 16,035 older and the 49,155 younger individuals, the median LDL cholesterol reduction was 1.7 mmol/L.
- Each 1 mmol/L reduction in LDL cholesterol in older individuals was significantly associated with a 23% lower risk of major vascular events (HR: 0.77), which was equal to that of younger individuals (HR: 0.76). Similar results were observed across all secondary analyses.
"Our study supports a relative clinical benefit of LDL cholesterol lowering for primary prevention of major vascular events in people aged ≥70 years similarly as in individuals aged <70 years," the researchers wrote. "Lipid-lowering conferred no reduction in mortality for either the young or the old."
Reference:
Andersson NW, et al "LDL-C reduction with lipid-lowering therapy for primary prevention of major vascular events among older individuals" J Am Coll Cardiol 2023; DOI: 10.1016/j.jacc.2023.07.027.
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751